AI Summary & Key Takeaways
AI InsightThe 5-year survival rate was 67.2% overall.Patients with stage IA1, IA2, IA3, and IB tumors had 5-year survival of 78.1%, 72.5%, 77.3%, and 56.7%, respectively (p=0.009).In multivariate analysis, advanced age (≥65 years), large cell carcinoma, left-sided surgery, and higher tumor stage were the mostimportant prognostic factors associated with poorer survival.Conclusion: Advanced age was determined to be an independent poor prognostic factor, and sub-group analyses showed that survivaloutcome was better with tumors smaller than 1 cm.
📌 3 Key Takeaways
Özet
Aim: This study aimed to evaluate prognostic factors influencing survival in patients who underwent surgical resection of stage I nonsmallcell lung cancer (NSCLC) in our center.Methods: A total of 472 patients with stage I NSCLC who were operated between January 2007 and November 2018 wereretrospectively analyzed in the study. Patient data was collected using hospital database. The remaining patients were divided into 2groups: patients younger than 65 years of age (group A) and those aged 65 and over (group B).Results: The patient group comprised 80 women (16.9%) and 392 men (83.1%); 152 patients were aged 65 years or over (32.2%) and320 patients were under 65 years of age (81.5%). The mean follow-up time was 51 months. The 5-year survival rate was 67.2% overall.Patients with stage IA1, IA2, IA3, and IB tumors had 5-year survival of 78.1%, 72.5%, 77.3%, and 56.7%, respectively (p=0.009).In multivariate analysis, advanced age (≥65 years), large cell carcinoma, left-sided surgery, and higher tumor stage were the mostimportant prognostic factors associated with poorer survival.Conclusion: Advanced age was determined to be an independent poor prognostic factor, and sub-group analyses showed that survivaloutcome was better with tumors smaller than 1 cm. Based on the results of our study, we believe that the classification of stage I groupshould be revised in the new edition of lung cancer staging.